BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,130 filers reported holding BAXTER INTL INC in Q1 2022. The put-call ratio across all filers is 1.41 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $23,000 | +15.0% | 268 | +7.2% | 0.00% | 0.0% |
| Q3 2021 | $20,000 | 0.0% | 250 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $20,000 | -4.8% | 250 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $21,000 | -82.5% | 250 | -83.3% | 0.00% | -66.7% |
| Q4 2020 | $120,000 | +100.0% | 1,500 | +100.0% | 0.00% | -25.0% |
| Q3 2020 | $60,000 | -7.7% | 750 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $65,000 | +6.6% | 750 | 0.0% | 0.00% | -20.0% |
| Q1 2020 | $61,000 | -52.7% | 750 | -50.0% | 0.01% | +25.0% |
| Q4 2019 | $129,000 | +95.5% | 1,500 | +100.0% | 0.00% | 0.0% |
| Q3 2019 | $66,000 | -48.0% | 750 | -51.6% | 0.00% | -50.0% |
| Q2 2019 | $127,000 | +0.8% | 1,550 | 0.0% | 0.01% | 0.0% |
| Q1 2019 | $126,000 | +23.5% | 1,550 | 0.0% | 0.01% | 0.0% |
| Q4 2018 | $102,000 | -14.3% | 1,550 | 0.0% | 0.01% | 0.0% |
| Q3 2018 | $119,000 | +4.4% | 1,550 | 0.0% | 0.01% | 0.0% |
| Q2 2018 | $114,000 | +12.9% | 1,550 | 0.0% | 0.01% | +14.3% |
| Q1 2018 | $101,000 | +1.0% | 1,550 | 0.0% | 0.01% | 0.0% |
| Q4 2017 | $100,000 | +3.1% | 1,550 | 0.0% | 0.01% | 0.0% |
| Q3 2017 | $97,000 | +3.2% | 1,550 | 0.0% | 0.01% | 0.0% |
| Q2 2017 | $94,000 | +17.5% | 1,550 | 0.0% | 0.01% | +16.7% |
| Q1 2017 | $80,000 | +15.9% | 1,550 | 0.0% | 0.01% | 0.0% |
| Q4 2016 | $69,000 | -6.8% | 1,550 | 0.0% | 0.01% | 0.0% |
| Q3 2016 | $74,000 | +5.7% | 1,550 | 0.0% | 0.01% | 0.0% |
| Q2 2016 | $70,000 | +4.5% | 1,550 | -5.0% | 0.01% | 0.0% |
| Q1 2016 | $67,000 | +8.1% | 1,631 | 0.0% | 0.01% | +20.0% |
| Q4 2015 | $62,000 | +21.6% | 1,631 | +5.2% | 0.01% | 0.0% |
| Q3 2015 | $51,000 | -52.8% | 1,550 | 0.0% | 0.01% | -44.4% |
| Q2 2015 | $108,000 | -19.4% | 1,550 | -20.5% | 0.01% | -18.2% |
| Q1 2015 | $134,000 | -76.1% | 1,950 | -74.5% | 0.01% | -75.0% |
| Q4 2014 | $561,000 | +3.5% | 7,650 | +1.3% | 0.04% | 0.0% |
| Q3 2014 | $542,000 | +1.3% | 7,550 | +2.0% | 0.04% | 0.0% |
| Q2 2014 | $535,000 | +13.6% | 7,400 | +15.6% | 0.04% | +7.3% |
| Q1 2014 | $471,000 | +27.6% | 6,400 | +20.8% | 0.04% | +24.2% |
| Q4 2013 | $369,000 | +37.2% | 5,300 | +29.3% | 0.03% | +26.9% |
| Q3 2013 | $269,000 | -5.3% | 4,100 | 0.0% | 0.03% | -10.3% |
| Q2 2013 | $284,000 | – | 4,100 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |